STOCK TITAN

Cymabay Therapeutics Inc - CBAY STOCK NEWS

Welcome to our dedicated news page for Cymabay Therapeutics (Ticker: CBAY), a resource for investors and traders seeking the latest updates and insights on Cymabay Therapeutics.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Cymabay Therapeutics's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Cymabay Therapeutics's position in the market.

Rhea-AI Summary
CymaBay Therapeutics, Inc. (NASDAQ: CBAY) announced the first published findings demonstrating the impact of seladelpar on serum interleukin-31 (IL-31) levels and its correlation with pruritus improvement in people with primary biliary cholangitis (PBC). The Phase 3 ENHANCE study showed statistically significant dose-dependent decreases in IL-31 with seladelpar compared to placebo. The findings were published in the open access journal Hepatology, marking a significant step in understanding the potential mediators of cholestatic itch and suggesting novel therapeutic approaches for PBC patients.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.08%
Tags
clinical trial
-
Rhea-AI Summary
CymaBay Therapeutics, Inc. (NASDAQ: CBAY) announces President and CEO Sujal Shah's presentation at the 42nd Annual JP Morgan Healthcare Conference on January 10, 2024, focusing on innovative therapies for liver and chronic diseases.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.38%
Tags
conferences
-
Rhea-AI Summary
CymaBay Therapeutics, Inc. (NASDAQ: CBAY) granted inducement awards to four employees on December 15, 2023. The Compensation Committee approved the grant of non-qualified stock options to purchase 176,000 shares of CymaBay common stock. The stock options have an exercise price of $22.03 per share and will vest over time based on the employees' continued employment.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
Rhea-AI Summary
CymaBay Therapeutics, Inc. (NASDAQ: CBAY) submits NDA for seladelpar, a potential treatment for primary biliary cholangitis. The NDA is supported by data from over 500 patients, with Phase 3 trial results demonstrating significant improvement in markers of cholestasis and PBC-related pruritus. Seladelpar has been granted Breakthrough Therapy Designation by the FDA and is the only potent, selective, orally active delpar with promising results in clinical trials.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.8%
Tags
none
-
Rhea-AI Summary
CymaBay Therapeutics, Inc. (NASDAQ: CBAY) announced the grant of inducement awards to five employees on November 15, 2023. The Compensation Committee approved the grant of non-qualified stock options to purchase 182,000 shares of CymaBay common stock. The options have an exercise price of $18.00 per share and will vest over time based on the employees' continued employment.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
Rhea-AI Summary
CymaBay Therapeutics, Inc. (NASDAQ: CBAY) announced positive results from the RESPONSE Phase 3 study on seladelpar for patients with primary biliary cholangitis (PBC). The study showed significant improvement in the primary composite endpoint, alkaline phosphatase normalization, and reductions in patient-reported pruritus compared to placebo. These results support the submission of global market authorization applications.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.5%
Tags
clinical trial
Rhea-AI Summary
CymaBay Therapeutics, Inc. (NASDAQ: CBAY) announced top-line results from the Phase 3 study in PBC, achieving primary and secondary endpoints with Breakthrough Therapy Designation for seladelpar. The company also completed a public offering of common stock and pre-funded warrants with net proceeds of $242.8 million. The Phase 3b/4 study AFFIRM was initiated to evaluate the effect of seladelpar on clinical outcomes in patients with cirrhosis due to PBC.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.5%
Tags
earnings
-
Rhea-AI Summary
CymaBay Therapeutics, Inc. (NASDAQ: CBAY) will be participating in three upcoming conferences: UBS Biopharma Conference on November 8-9th, Piper Sandler 35th Annual Healthcare Conference on November 28-30th, and Evercore ISI 6th Annual HealthCONx Conference on November 28-30th. The management team will engage in fireside chats and webcasts during these events.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.49%
Tags
conferences
-
Rhea-AI Summary
CymaBay Therapeutics announces two-year safety and efficacy results of seladelpar for primary biliary cholangitis (PBC). The study showed that 63% and 79% of patients achieved the composite endpoint after one and two years, respectively. ALP normalization was achieved in 23% and 42% of patients at one and two years, respectively. Sustained reductions in ALT and AST were observed. The long-term treatment with seladelpar resulted in continued improvement in markers of cholestasis and liver injury.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.12%
Tags
none
Rhea-AI Summary
CymaBay Therapeutics, Inc. will host a conference call and live webcast on November 7, 2023, to discuss financial results for Q3 2023 and provide a business update.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.12%
Tags
conferences earnings
Cymabay Therapeutics Inc

Nasdaq:CBAY

CBAY Rankings

CBAY Stock Data

3.73B
96.64M
0.52%
103.13%
5.1%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
US
Newark

About CBAY

cymabay therapeutics is a clinical-stage biopharmaceutical company located in the san francisco bay area focused on developing therapies to treat metabolic diseases with high unmet medical need or serious rare and orphan diseases. we are committed to developing breakthrough medicines that improve the lives of patients and their families. cymabay was seeded with the assets from an earlier metabolic disease company in which more than $120m was invested to produce a robust pipeline.